US Stock MarketDetailed Quotes

NUGX NUGENEREX IMMUNO-ONCOLOGY INC

Watchlist

0.000100
0.0000000.00%

15min DelayClose May 24 09:30 ET

10.03KMarket Cap-1P/E (TTM)

NUGENEREX IMMUNO-ONCOLOGY INC Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual

YOY

Hide blank lines

(Q3)Apr 30, 2021

(Q2)Jan 31, 2021

(Q1)Oct 31, 2020

(FY)Jul 31, 2020

(Q4)Jul 31, 2020

(Q3)Apr 30, 2020

(Q2)Jan 31, 2020

(Q1)Oct 31, 2019

(FY)Jul 31, 2019

(Q4)Jul 31, 2019

Operating Cash Flow (Indirect Method)

Cash flow from continuing operating activities

99.98%-39

-100.02%-45

52.04%-305

0.00%-45

-214.55K

214.34K

-636

-45

Net income from continuing operations

-537.84%-1.96M

-310.81%-2.08M

-546.58%-1.74M

-43.39%-1.59M

-158.64%-506.11K

-47.85%-307.07K

---506.75K

---268.88K

---1.11M

---195.68K

Change In working capital

537.94%1.96M

612.44%2.08M

259.77%1.74M

43.45%1.59M

158.67%506.06K

47.86%307.03K

--292.2K

--483.22K

--1.11M

--195.64K

-Change in prepaid assets

----

---20K

----

--0

----

-Change in payables and accrued expense

551.37%2M

605.59%2.06M

263.91%1.76M

43.45%1.59M

158.67%506.06K

47.86%307.03K

--292.2K

--483.22K

--1.11M

--195.64K

Cash from discontinued investing activities

Operating cash flow

--0

99.98%-39

-100.02%-45

52.04%-305

0.00%-45

---214.55K

--214.34K

---636

---45

Investing cash flow

Cash flow from continuing investing activities

Cash from discontinued investing activities

Financing cash flow

Cash flow from continuing financing activities

Cash from discontinued financing activities

Net cash flow

Beginning cash position

--0

-99.98%39

-78.41%84

-62.05%389

-70.28%129

-63.67%174

--214.73K

--389

--1.03K

--434

Current changes in cash

--0

99.98%-39

-100.02%-45

52.04%-305

0.00%-45

---214.55K

--214.34K

---636

---45

End cash Position

--0

-99.98%39

-78.41%84

-70.28%129

--174

--214.73K

--389

Free cash flow

--0

99.98%-39

-100.02%-45

52.04%-305

0.00%-45

---214.55K

--214.34K

---636

---45

Currency Unit

USD

Audit Opinions

Unqualified Opinion with Explanatory Notes

	(Q3)Apr 30, 2021	(Q2)Jan 31, 2021	(Q1)Oct 31, 2020	(FY)Jul 31, 2020	(Q4)Jul 31, 2020	(Q3)Apr 30, 2020	(Q2)Jan 31, 2020	(Q1)Oct 31, 2019	(FY)Jul 31, 2019	(Q4)Jul 31, 2019
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities	0	99.98%-39	-100.02%-45	52.04%-305	0.00%-45	0.00%-45	-214.55K	214.34K	-636	-45
Net income from continuing operations	-537.84%-1.96M	-310.81%-2.08M	-546.58%-1.74M	-43.39%-1.59M	-158.64%-506.11K	-47.85%-307.07K	---506.75K	---268.88K	---1.11M	---195.68K
Change In working capital	537.94%1.96M	612.44%2.08M	259.77%1.74M	43.45%1.59M	158.67%506.06K	47.86%307.03K	--292.2K	--483.22K	--1.11M	--195.64K
-Change in prepaid assets	----	----	---20K	----	----	----	----	--0	----	----
-Change in payables and accrued expense	551.37%2M	605.59%2.06M	263.91%1.76M	43.45%1.59M	158.67%506.06K	47.86%307.03K	--292.2K	--483.22K	--1.11M	--195.64K
Cash from discontinued investing activities
Operating cash flow	--0	99.98%-39	-100.02%-45	52.04%-305	0.00%-45	0.00%-45	---214.55K	--214.34K	---636	---45
Investing cash flow
Cash flow from continuing investing activities
Cash from discontinued investing activities
Financing cash flow
Cash flow from continuing financing activities
Cash from discontinued financing activities
Net cash flow
Beginning cash position	--0	-99.98%39	-78.41%84	-62.05%389	-70.28%129	-63.67%174	--214.73K	--389	--1.03K	--434
Current changes in cash	--0	99.98%-39	-100.02%-45	52.04%-305	0.00%-45	0.00%-45	---214.55K	--214.34K	---636	---45
End cash Position	--0	--0	-99.98%39	-78.41%84	-78.41%84	-70.28%129	--174	--214.73K	--389	--389
Free cash flow	--0	99.98%-39	-100.02%-45	52.04%-305	0.00%-45	0.00%-45	---214.55K	--214.34K	---636	---45
Currency Unit	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Audit Opinions	--	--	--	Unqualified Opinion with Explanatory Notes	--	--	--	--	--	--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall